NCT02494882View on ClinicalTrials.gov

Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 29, 2015

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

Ruxolitinib

DRUG

Dasatinib

DRUG

Dexamethasone

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER